Theravance Biopharma, Inc. Analyst EPS Estimates
Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
---|---|---|---|---|
Q1 2024 | 0 | -$0.28 | -$0.22 | -$0.25 |
Q2 2024 | 0 | -$0.23 | -$0.18 | -$0.21 |
Q3 2024 | 3 | -$0.28 | -$0.18 | -$0.23 |
Q4 2024 | 0 | $0.04 | $0.05 | $0.05 |
Q1 2025 | 2 | -$0.28 | -$0.22 | -$0.25 |
Q2 2025 | 2 | -$0.30 | -$0.24 | -$0.27 |
Q3 2025 | 2 | -$0.19 | -$0.15 | -$0.17 |
Q4 2025 | 2 | $0.02 | $0.02 | $0.02 |
Theravance Biopharma, Inc. Earnings Date And Information
Theravance Biopharma, Inc. last posted its earnings results on Monday, August 5th, 2024. The company reported $-0.13 earnings per share for the quarter, missing analysts' consensus estimates of $-0.09 by $0.04. The company had revenue of 14.26 M for the quarter and had revenue of 57.42 M for the year. Theravance Biopharma, Inc. has generated $-1 earnings per share over the last year ($-1 diluted earnings per share) and currently has a price-to-earnings ratio of -8.61. Theravance Biopharma, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 4th, 2024 based on prior year's report dates.
Theravance Biopharma, Inc. Earnings History by Quarter
Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
08/08/2024 | Q2 2024 | -$0.34 | $15.38 M | $14.26 M | ||
05/15/2024 | Q1 2024 | -$0.24 | $14.50 M | |||
03/01/2024 | Q4 2023 | -$0.17 | $17.57 M | |||
11/09/2023 | Q3 2023 | -$0.17 | $15.40 M | $15.69 M | ||
08/09/2023 | Q2 2023 | -$0.28 | $15.29 M | $13.75 M | ||
05/10/2023 | Q1 2023 | -$0.35 | $10.42 M | |||
03/01/2023 | Q4 2022 | -$0.21 | $14.65 M | |||
11/09/2022 | Q3 2022 | $12.14 | $11.81 M | $12.45 M | ||
08/08/2022 | Q2 2022 | -$0.11 | $11.05 M | |||
05/06/2022 | Q1 2022 | -$0.34 | $13.20 M | |||
02/28/2022 | Q4 2021 | -$0.44 | $13.49 M | $14.95 M | ||
11/08/2021 | Q3 2021 | -$0.48 | $14.40 M | $13.19 M | ||
08/05/2021 | Q2 2021 | -$0.80 | $15.41 M | $12.91 M | ||
05/06/2021 | Q1 2021 | -$1.24 | $14.26 M | |||
02/26/2021 | Q4 2020 | -$0.92 | $19.87 M | $18.73 M | ||
11/09/2020 | Q3 2020 | -$1.16 | $18.58 M | $18.26 M | ||
08/10/2020 | Q2 2020 | -$1.00 | $19.64 M | $15.01 M | ||
05/08/2020 | Q1 2020 | -$1.40 | $19.86 M | |||
02/27/2020 | Q4 2019 | -$1.17 | $16.84 M | $29.50 M | ||
11/08/2019 | Q3 2019 | -$1.05 | $11.62 M | $12.43 M |
Theravance Biopharma, Inc. Earnings: Frequently Asked Questions
-
When is Theravance Biopharma, Inc.'s earnings date?
Theravance Biopharma, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 4th, 2024 based off last year's report dates.
-
How can I listen to Theravance Biopharma, Inc.'s earnings conference call?
The conference call for Theravance Biopharma, Inc.'s latest earnings report can be listened to online.
-
How can I read Theravance Biopharma, Inc.'s conference call transcript?
The conference call transcript for Theravance Biopharma, Inc.'s latest earnings report can be read online.
-
How much revenue does Theravance Biopharma, Inc. generate each year?
Theravance Biopharma, Inc. (:TBPH) has a recorded annual revenue of $57.42 M.
-
How much profit does Theravance Biopharma, Inc. generate each year?
Theravance Biopharma, Inc. (:TBPH) has a recorded net income of $57.42 M. Theravance Biopharma, Inc. has generated $-1 earnings per share over the last four quarters.
-
What is Theravance Biopharma, Inc.'s price-to-earnings ratio?
Theravance Biopharma, Inc. (:TBPH) has a price-to-earnings ratio of -8.61 and price/earnings-to-growth ratio is -0.42.